1. Academic Validation
  2. SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis

SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis

  • Cell Death Dis. 2018 Sep 24;9(10):982. doi: 10.1038/s41419-018-0962-6.
Xiaoxiang Chen 1 2 Kaixuan Zeng 1 2 Mu Xu 1 Xiuxiu Hu 1 2 Xiangxiang Liu 1 Tao Xu 1 Bangshun He 1 Yuqin Pan 1 Huiling Sun 1 Shukui Wang 3
Affiliations

Affiliations

  • 1 General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, Jiangsu, China.
  • 2 Medical College, Southeast University, Nanjing, 210009, Jiangsu, China.
  • 3 General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, Jiangsu, China. [email protected].
Abstract

Increasing long non-coding RNAs (lncRNAs) have been reported to play key roles in the development and progression of various malignancies. ZNFX1 antisense RNA1 (ZFAS1) has been reported to be aberrant expression and suggested as a tumor suppressor or oncogene in many cancers. However, the biological role and underlying molecular mechanism of ZFAS1, especially the miRNA Sponge role of which in CRC remain largely unknown. We found that ZFAS1 expression was higher in CRC tissues, where it was associated with poor overall survival (OS), we also showed that ZFAS1 upregulation was induced by nuclear transcription factor SP1. Moreover, ZFAS1 and VEGFA are both targets of miR-150-5p, while ZFAS1 binds to miR-150-5p in an AGO2-dependent manner. Additionally, ZFAS1 upregulation markedly promoted as well as ZFAS1 knockdown significantly suppressed CRC cell proliferation, migration, invasion and angiogenesis, and the inhibitory effect caused by ZFAS1 knockdown could be reversed by antagomiR-150-5p. Lastly, we demonstrated that ZFAS1 knockdown inhibited EMT process and inactivated VEGFA/VEGFR2/KDR/Flk-1 and downstream Akt/mTOR signaling pathway in CRC. Our data demonstrated that SP1-induced ZFAS1 contributed to CRC progression by upregulating VEGFA via competitively binding to miR-150-5p, which acts as a tumor suppressor by targeting VEGFA in CRC.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12038
    98.15%, VEGFR Inhibitor